Back to top
more

Merit Medical Systems (MMSI)

(Delayed Data from NSDQ)

$83.75 USD

83.75
450,742

+1.35 (1.64%)

Updated May 15, 2024 04:00 PM ET

After-Market: $83.71 -0.04 (-0.05%) 7:00 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value B Growth B Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 41% (147 out of 250)

Industry: Medical - Dental Supplies

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

What's in Store for DENTSPLY SIRONA (XRAY) in Q4 Earnings?

by Zacks Equity Research

DENTSPLY SIRONA's (XRAY) fourth-quarter 2023 results are likely to reflect a recovery in demand for consumable products, partially offset by lower sales in China due to volume-based procurement policy.

Stay Ahead of the Game With Merit Medical (MMSI) Q4 Earnings: Wall Street's Insights on Key Metrics

by Zacks Equity Research

Besides Wall Street's top -and-bottom-line estimates for Merit Medical (MMSI), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended December 2023.

The Cooper Companies (COO) Earnings Expected to Grow: Should You Buy?

by Zacks Equity Research

The Cooper Companies (COO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Merit Medical (MMSI) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

by Zacks Equity Research

Merit Medical (MMSI) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Merit Medical's (MMSI) SCOUT Guidance System Gets FDA Nod

by Zacks Equity Research

Merit Medical's (MMSI) SCOUT MD Surgical Guidance System receives FDA clearance, which aims to boost the treatment of breast cancer by increasing accuracy to target tumor sites.

West Pharmaceutical Services (WST) Beats Q4 Earnings Estimates

by Zacks Equity Research

West Pharmaceutical (WST) delivered earnings and revenue surprises of 2.81% and 0.93%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

What's in Store for West Pharmaceutical (WST) in Q4 Earnings?

by Zacks Equity Research

West Pharmaceutical's (WST) fourth-quarter 2023 results are likely to reflect strength in the Proprietary Products business. However, unfavorable currency movements might have hurt the top and bottom lines.

What's in the Cards for Medtronic (MDT) in Q3 Earnings?

by Zacks Equity Research

Strength in all four businesses is likely to drive Medtronic's (MDT) fiscal third-quarter performance.

Here's Why You Should Add HealthEquity (HQY) to Your Portfolio

by Zacks Equity Research

HealthEquity's (HQY) strength in HSA raises optimism about the stock.

Insulet (PODD) to Report Q4 Earnings: What's in the Cards?

by Zacks Equity Research

Insulet (PODD) is expected to have benefited from the ongoing rollout of Omnipod 5 in several international markets in the fourth quarter.

MMSI vs. ALGN: Which Stock Is the Better Value Option?

by Zacks Equity Research

MMSI vs. ALGN: Which Stock Is the Better Value Option?

Ecolab (ECL) to Report Q4 Earnings: What's in the Cards?

by Zacks Equity Research

Ecolab's (ECL) fourth-quarter results are likely to be driven by its Food & Beverage, Water business along with the Institutional segment.

DaVita (DVA) to Report Q4 Earnings: What's in the Offing?

by Zacks Equity Research

Improvement in revenue per treatment and cost-saving initiatives are likely to have boosted DaVita's (DVA) top line in the fourth quarter.

Are You a Value Investor? This 1 Stock Could Be the Perfect Pick

by Zacks Equity Research

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Insulet's (PODD) Omnipod 5 Gets CE Mark for Added Compatibility

by Zacks Equity Research

Insulet's (PODD) tubeless automated insulin delivery system's CE mark approval with multiple CGM sensor brands is likely to serve a wider patient pool.

Labcorp (LH) to Report Q4 Earnings: What's in the Cards? (Revised)

by Zacks Equity Research

Labcorp's (LH) fourth-quarter 2023 performance is likely to have demonstrated strength across its core businesses.

Three Reasons to Retain BD (BDX) Stock in Your Portfolio

by Zacks Equity Research

BD's (BDX) slew of product launches raises optimism about the stock.

McKesson (MCK) to Report Q3 Earnings: What's in the Cards?

by Zacks Equity Research

McKesson's (MCK) third-quarter fiscal 2024 results are likely to reflect the solid display by the U.S. Pharmaceutical and Specialty Solutions segment.

Catalent (CTLT) to Report Q2 Earnings: What's in the Cards?

by Zacks Equity Research

Catalent's (CTLT) fiscal second-quarter results are likely to be driven by its non-COVID non-Sarepta Biologics business.

Modular Medical (MODD) Pairing Technology Issued New U.S. Patent

by Zacks Equity Research

Modular Medical's (MODD) latest U.S. patent is likely to protect the company's technology addressing pairing and allow clinicians to easily upload and review patients' data.

Baxter (BAX) to Report Q4 Earnings: What's in the Cards?

by Zacks Equity Research

Baxter's (BAX) fourth-quarter results are likely to reflect growth in elective surgical procedures, offset by currency movement. Hillrom's products might have boosted sales.

DexCom (DXCM) to Report Q4 Earnings: Is a Beat in Store?

by Zacks Equity Research

DexCom's (DXCM) fourth-quarter 2023 results are likely to reflect rising volumes across all channels.

Labcorp (LH) to Report Q4 Earnings: What's in the Cards?

by Zacks Equity Research

Labcorp's (LH) fourth-quarter 2023 performance is likely to have demonstrated strength across its core businesses.

GE HealthCare (GEHC) to Report Q4 Earnings: What's in Store?

by Zacks Equity Research

GE HealthCare (GEHC) is expected to report strong organic revenue growth, banking on balanced segmental performance, driven by consistent NPIs and growing customer demand.

Why Merit Medical (MMSI) Could Beat Earnings Estimates Again

by Zacks Equity Research

Merit Medical (MMSI) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.